Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1990-07-31
1992-05-12
Ford, John M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
544353, 544354, 548351, A61K 31495, C07D40310
Patent
active
051128225
ABSTRACT:
A compound selected from the group consisting of those having the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof, wherein R.sub.1 and R.sub.4 are independently selected from the group consisting of H and alkyl radicals having 1 to 4 carbon atoms; the R.sub.2 s are each H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the R.sub.3 s are each H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo, provided that the R.sub.2 s or the R.sub.3 s are alkyl radicals; the 2-imidazolin-2-ylamino group may be in any of the 5-, 6, 7- or 8-positions of the quinoxaline nucleus; and R.sub.5, R.sub.6 and R.sub.7 each is located in one of the remaining 5-, 6-, 7- or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals having 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as alteration in the rate of fluid transport in the gastrointestinal tract, reduction in intraocular pressure, and increase in renal fluid flow.
REFERENCES:
patent: 3890319 (1975-06-01), Danielewicz et al.
patent: 5021416 (1991-06-01), Gluchowski
Fielding, "Clonidine:New Research in Psychotropic Drug Pharmacology, Medicinal Research Reviews", vol. 1, No. 1 pp. 97-123 (1981).
Isom et al., "a2-Adrenergic Receptors Accelerate Na/H Exchange in Neuroblastoma X Glioma Cells", The Journal of Biological Chemistry, vol. 262, No. 14, issue of May 15, 1987, pp. 6750-6757.
Pieter et al., "Clonidine and Some Bridge Analogues; Cardiovascular Effects and Nuclear Magnetic Resonance Data (.sup.1 H/.sup.13)", Eur. J. Med. Chem, Jul.-Aug. 1980, vol. 4, pp. 323-329.
Jumblatt et al., "Alpha-2 Adrenergic Modulation of Norepinephrine Secretion in the Perfused Rabbit Iris-Ciliary Body", Current Eye Research, 1987, vol. 6, pp. 767-777.
Burke et al., "Ocular Effects of a Relatively Selective a2 Agonist (UK-14, 304-18) in Cats, Rabbits and Monkeys", Current Eye Research, 1986, vol. 5, pp. 665-676.
Fondacaro et al., "Selective Alpha-2 Adrenoceptor Agonists Alter Fluid and Electrolyte Transport in Mammalian Small Intestine American Society for Pharmacology", vol. 247, p. 481 (1988).
Gellai et al., "Mechanism of a2-Adrenoceptor Agonist-Induced Diuresis American Physiological Society 1988".
Dharmsathaphorn, a2-Adrenergic Agonists: A Newer Class of Antidiarrheal Drug Gastroenterology 1986, vol. 91, pp. 769-775.
Mittag, "Ocular Effects of Selective Alpha-Adrenergic Agents: A New Drug Paradox", Annals of Ophthalmology Mar. 1983, p. 201.
Gellai et al., "Renal Effects of Selective Alpha-1 and Alpha-2 Adrenoceptor Agonists in Conscious Normotensive Rats", The Journal of Pharmacology, vol. 240, p. 723 (1987).
Jarrot, "Clonidine and Related Compounds", Handbook of Hypertension, vol. 5, p. 113 (1984).
Allergan Inc.
Bernhardt E.
Ford John M.
Peterson Gordon L.
Uxa, Jr. Frank J.
LandOfFree
(2-imidazolin-2-ylamino) quinoxaline derivatives and methods for does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2426181